JNJ 61610588

Drug Profile

JNJ 61610588

Alternative Names: JNJ-61610588

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Aug 2017 Janssen Research and Development terminates a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, France and Spain due to business reasons (NCT02671955)
  • 23 Jan 2017 Janssen reinitiates enrolment in a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02671955)
  • 09 Dec 2016 Janssen suspends enrolment in a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02671955)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top